Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 1
1994 4
1995 2
1996 1
1997 3
1998 5
1999 9
2000 9
2001 15
2002 18
2003 9
2004 7
2005 8
2006 10
2007 6
2008 3
2009 7
2010 3
2011 4
2012 4
2013 5
2014 6
2015 4
2016 3
2022 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for valmori d[au]
Your search for Balmori D[au] retrieved no results
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Löffler MW, et al. Among authors: valmori d. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424. Clin Cancer Res. 2022. PMID: 35421231 Clinical Trial.
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor.
Pittet MJ, Zippelius A, Valmori D, Speiser DE, Cerottini JC, Romero P. Pittet MJ, et al. Among authors: valmori d. Trends Immunol. 2002 Jul;23(7):325-8. doi: 10.1016/s1471-4906(02)02244-5. Trends Immunol. 2002. PMID: 12103339 Review. No abstract available.
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC. Romero P, et al. Among authors: valmori d. Immunol Rev. 2002 Oct;188:81-96. doi: 10.1034/j.1600-065x.2002.18808.x. Immunol Rev. 2002. PMID: 12445283 Review.
Consensus nomenclature for CD8+ T cell phenotypes in cancer.
Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Apetoh L, et al. Among authors: valmori d. Oncoimmunology. 2015 Feb 25;4(4):e998538. doi: 10.1080/2162402X.2014.998538. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137416 Free PMC article.
IL-1beta and IL-2 convert human Treg into T(H)17 cells.
Deknuydt F, Bioley G, Valmori D, Ayyoub M. Deknuydt F, et al. Among authors: valmori d. Clin Immunol. 2009 May;131(2):298-307. doi: 10.1016/j.clim.2008.12.008. Epub 2009 Feb 11. Clin Immunol. 2009. PMID: 19211307
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K. Qian F, et al. Among authors: valmori d. Cancer Res. 2009 Jul 1;69(13):5498-504. doi: 10.1158/0008-5472.CAN-08-2106. Epub 2009 Jun 2. Cancer Res. 2009. PMID: 19491279
SSX antigens as tumor vaccine targets in human sarcoma.
Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS, Valmori D. Ayyoub M, et al. Among authors: valmori d. Cancer Immun. 2003 Oct 9;3:13. Cancer Immun. 2003. PMID: 14533943
CD4+ T cell responses to SSX-4 in melanoma patients.
Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. Ayyoub M, et al. Among authors: valmori d. J Immunol. 2005 Apr 15;174(8):5092-9. doi: 10.4049/jimmunol.174.8.5092. J Immunol. 2005. PMID: 15814740
140 results